- Source : Press Release
- Date : 2022-04-19
- Event type : Phase 3
- Companies : Evotec SE, Zhejiang Jingxin Pharmaceutical Co., Ltd., Roche
Jingxin Pharmaceutical Signed a Cooperation Agreement with Germany's Evotec to Expand the Global Licensing Scope of EVT201
Recently, Jingxin Pharmaceutical signed an agreement with German Evotec SE (hereinafter referred to as "Evotec").
1. Introduce product information
EVT201 is a new class 1 small molecule drug for the treatment of adult insomnia. It is a partial agonist of GABAA (γ-aminobutyric acid A) receptors and selectively acts on the α1 subtype of benzodiazepine receptors with high affinity and Moderate agonistic effect, induces rapid onset and maintenance of sleep. Compared with traditional benzodiazepine GABA receptor full agonists, it has obvious advantages in adverse reactions such as dyskinesia, sequelae effects, tolerance, ethanol interaction, physical dependence, and memory impairment.
Jingxin Pharmaceutical has completed the Phase 3 clinical trial in China and achieved the primary and secondary endpoints, and EVOTEC has also completed the Phase 2 clinical trial abroad.
The main symptoms of insomnia are difficulty falling asleep (latency to fall asleep more than 30 minutes), sleep maintenance disturbance (≥2 awakenings throughout the night), early going to bed, decreased sleep quality, and decreased total sleep time (usually less than 6.5 hours), accompanied by Daytime dysfunction.
2. Main content of the agreement
According to the agreement, the company will obtain the exclusive development, production and commercialization rights of EVT201 in South Korea and other countries around the world. For expansion territories, the company will pay Evotec an down payment and milestone payments, as well as a share of net sales within the authorized territories.
This transaction will expand the global scope of the insomnia drug EVT201, accelerate the global commercialization of EVT201, and benefit more insomnia patients. At the same time, it will further accelerate the pace of the company's internationalization, enhance the company's international influence, and help the company's innovation and transformation.
3. About Evotec
Evotec is a life sciences company with a unique business model focused on delivering highly effective new therapies to patients. The company leverages its multimodal platform "Data-Driven R&D Solutions" to serve proprietary projects as well as partners including pharma, biotech, academia and more. Headquartered in Hamburg, Germany, Evotec employs more than 4,000 people in 14 locations worldwide. Listed on Nasdaq in November 2021 under the ticker symbol EVO.
In the future, Jingxin Pharmaceutical will continue to focus on the fields of mental and neurological, cardiovascular and cerebrovascular, and increase the cultivation of products in the core fields, driven by pharmaceutical research and development and technological innovation, and make positive contributions to the cause of human health.